COMMUNIQUÉS West-GlobeNewswire
-
Cannara annoncera ses résultats financiers du quatrième trimestre et de l'exercice 2026 le 30 novembre 2026
16/11/2026 -
Cannara to Announce Fiscal Q4 and Fiscal Year 2026 Financial Results on November 30, 2026
16/11/2026 -
Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel
16/11/2026 -
Enlivex Announces Pricing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
16/11/2026 -
Iambic Provides Business Updates and Third Quarter 2026 Financial Results
16/11/2026 -
Commure Acquires Elaborate to Cure the Clinician Inbox
16/11/2026 -
ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update
16/11/2026 -
Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update
16/11/2026 -
Pluri CEO Letter: Turning Our Cell Technology and Experience into Commercial Opportunity
16/11/2026 -
MediWound to Host Virtual KOL Event on EscharEx® Phase III VALUE Study and Commercial Opportunity on December 2, 2026
16/11/2026 -
NewGen Provides Business Update
16/11/2026 -
U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults
16/11/2026 -
Former Cross Country Healthcare CEO Bill Grubbs Takes Expanded Role as LUKE Executive Chairman
16/11/2026 -
Dr. Robert Langer, Co-Founder of Moderna, Joins PolarityBio’s Board of Directors
16/11/2026 -
Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026
16/11/2026 -
IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
16/11/2026 -
PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
16/11/2026 -
Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
16/11/2026 -
Akebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 Million
16/11/2026
Pages